Infliximab improves QOL in active and fistulising Crohn's disease

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1346, 2002-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Budesonide improves QOL in Crohn's disease

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 360, 2002-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Infliximab promising in paediatric Crohn's disease

By  

Inpharma, Vol. 1, Iss. 1391, 2003-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Infliximab: additional benefits in Crohn's disease

By  

Inpharma, Vol. 1, Iss. 1349, 2002-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Infliximab worth it for Crohn's disease in the UK

By  

Inpharma, Vol. 1, Iss. 1515, 2005-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn's Disease

By Yu Andrew P.  

PharmacoEconomics, Vol. 27, Iss. 7, 2009-07 ,pp. : 609-621

Adis International

Access to resources Recommend Favorite